{"id":1893,"date":"2024-08-30T21:56:24","date_gmt":"2024-08-30T19:56:24","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/calismaya-genel-bakis\/"},"modified":"2026-02-13T12:25:35","modified_gmt":"2026-02-13T11:25:35","slug":"calismaya-genel-bakis","status":"publish","type":"page","link":"https:\/\/studienportal-eierstockkrebs.de\/tr\/calismaya-genel-bakis\/","title":{"rendered":"\u00c7al\u0131\u015fmaya genel bak\u0131\u015f"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u00c7al\u0131\u015fmaya genel bak\u0131\u015f<\/strong>
Yumurtal\u0131k kanseri<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Burada yumurtal\u0131k kanseri alan\u0131ndaki t\u00fcm g\u00fcncel \u00e7al\u0131\u015fmalar\u0131n bir listesini bulacaks\u0131n\u0131z:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u0130lk tedavi<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n

AGO-OVAR 27- WoO<\/a><\/h3><\/header>
\n

AGO-OVAR 27 – WoO WoO: Histolojik olarak kan\u0131tlanm\u0131\u015f EOC’de olaparib ve durvalumab \u00fczerine F\u0131rsat Penceresi \u00e7al\u0131\u015fmas\u0131 AGO-ovar 27 \u00e7al\u0131\u015fmas\u0131n\u0131n A kohortu Ocak 2025’ten bu yana tamamen i\u015fe al\u0131nm\u0131\u015ft\u0131r. B kohortunda...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

NOGGO ov54 – SCOUT-1<\/a><\/h3><\/header>
\n

NOGGO ov54 – \u0130zci 1 Ba\u015flang\u0131\u00e7 tedavisi g\u00f6ren yumurtal\u0131k kanserli hastalar\u0131n g\u00fcnl\u00fck rutinlerinden veri toplamaya y\u00f6nelik g\u00f6zlemsel \u00e7al\u0131\u015fma SCOUT-1, yumurtal\u0131k kanserli hastalar\u0131n g\u00fcnl\u00fck rutininden klinik ve hasta taraf\u0131ndan bildirilen verileri...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

N-PLUS<\/a><\/h3><\/header>
\n

NOGGO ov53\/ ENGOT-ov62 – N-Plus T\u00fcm\u00f6rs\u00fcz cerrahi ge\u00e7irmi\u015f hastalarda kemoterapi d\u00f6ng\u00fclerinin say\u0131s\u0131n\u0131 ve dolay\u0131s\u0131yla kemoterapi s\u00fcresini azaltmay\u0131 ama\u00e7layan d\u00fcnyan\u0131n ilk \u00e7al\u0131\u015fmas\u0131. N-Plus, ilerlemi\u015f yumurtal\u0131k kanseri i\u00e7in ba\u015flang\u0131\u00e7 tedavisi g\u00f6ren HRD-pozitif...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

NIS CAROLIN<\/a><\/h3><\/header>
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN Platine duyarl\u0131 yumurtal\u0131k kanseri olan ve niraparib i\u00e7in kontrendikasyonu bulunmayan hastalar i\u00e7in Bu giri\u015fimsel olmayan g\u00f6zlemsel \u00e7al\u0131\u015fman\u0131n amac\u0131, ilk kez tan\u0131 konmu\u015f veya n\u00fcksetmi\u015f...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

AGO-OVAR 28 \/ ENGOT-OV57<\/a><\/h3><\/header>
\n

AGO-OVAR 28 \/ ENGOT-OV57 Yeni tan\u0131 konmu\u015f ileri evre yumurtal\u0131k kanseri i\u00e7in kemoterapi alan hastalarda tek ba\u015f\u0131na niraparib ile niraparib ve bevacizumab kombinasyonunu de\u011ferlendiren randomize a\u00e7\u0131k etiketli bir faz III...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

N\u00fcks tedavisi<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN<\/a><\/h3><\/header>
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN Platine duyarl\u0131 yumurtal\u0131k kanseri olan ve niraparib i\u00e7in kontrendikasyonu bulunmayan hastalar i\u00e7in Bu giri\u015fimsel olmayan g\u00f6zlemsel \u00e7al\u0131\u015fman\u0131n amac\u0131, ilk kez tan\u0131 konmu\u015f veya n\u00fcksetmi\u015f...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

ENGOT-ov83 \/ CATALINA-2<\/a><\/h3><\/header>
\n

ENGOT-ov83 \/ CATALINA-2 \u0130lerlemi\u015f, platine diren\u00e7li yumurtal\u0131k kanseri hastalar\u0131nda yeni bile\u015fik TORL-1-23’\u00fcn etkinli\u011fini ve g\u00fcvenli\u011fini de\u011ferlendirmek i\u00e7in terap\u00f6tik \u00e7al\u0131\u015fma CATALINA-2 , ilerlemi\u015f, platine diren\u00e7li yumurtal\u0131k kanseri (yumurtal\u0131k, fallop t\u00fcp\u00fc veya...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

ENGOT-ov47-TR\/ NOGGO-TR2 – YARDIM-ER<\/a><\/h3><\/header>
\n

ENGOT-ov47-TR\/ NOGGO-TR2 – YARDIM-ER YUMURTALIK KANSERI\u0307NI\u0307N I\u0307LK N\u00dcKS\u00dc OLAN HASTALARIN KANINDAKI\u0307 HE4 SERUM D\u00dcZEYLERI\u0307 \u00dcZERI\u0307NE G\u00d6ZLEMSEL \u00c7ALI\u015eMA HELP-ER \u00e7al\u0131\u015fmas\u0131, platine duyarl\u0131 yumurtal\u0131k kanserinin ilk n\u00fcksetmesi olan hastalar\u0131n tedavisini iyile\u015ftirmek i\u00e7in...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301<\/a><\/h3><\/header>
\n

AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301 TEKRARLAYAN D\u00dc\u015e\u00dcK DERECELI\u0307 SER\u00d6Z OVER KARSI\u0307NOMU \u00dcZERI\u0307NE KLI\u0307NI\u0307K \u00c7ALI\u015eMA AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301, tekrarlayan d\u00fc\u015f\u00fck dereceli ser\u00f6z over kanseri (LGSOC)...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

NOGGO S15 – FraStROC<\/a><\/h3><\/header>
\n

NOGGO S15 – FraStROC Tekrarlayan veya n\u00fckseden yumurtal\u0131k kanseri olan hastalar i\u00e7in \u00e7al\u0131\u015fma. TEKRARLAYAN VEYA N\u00dcKSEDEN YUMURTALIK KANSERI OLAN HASTALAR I\u00c7IN \u00c7ALI\u015eMA FraStROC \u00e7al\u0131\u015fmas\u0131, yumurtal\u0131k kanseri hastalar\u0131n\u0131n kemoterapi s\u0131ras\u0131nda n\u00fcks...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Anketler<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n

\u0130fade XVIII (18)<\/a><\/h3><\/header>
\n

NOGGO S30\/ \u0130fade XVIII (18) JI\u0307NEKOLOJI\u0307K T\u00dcM\u00d6RL\u00dc HASTALAR \u00dcZERI\u0307NDE KRI\u0307ZLERI\u0307N ETKI\u0307SI\u0307NE I\u0307LI\u0307\u015eKI\u0307N ULUSLARARASI ARA\u015eTIRMA Anksiyete, jinekolojik hastal\u0131klar\u0131 olan kanser hastalar\u0131 i\u00e7in merkezi bir konudur ve sava\u015f, mali durum ve pandemi...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

IFADE IX (9)<\/a><\/h3><\/header>
\n

NOGGO S20 \/ ENGOTgyn4 – EXPRESSION IX (9) Jinekolojik kanserde uzun s\u00fcreli sa\u011fkal\u0131m \/ Jinekolojik kanserde uzun s\u00fcreli sa\u011fkalanlar Yumurtal\u0131k kanserinden uzun s\u00fcreli kurtulanlara odaklanan bir anket olan Expression VI...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

NOGGO S19 – I\u0307FADE VIII (8)<\/a><\/h3><\/header>
\n

NOGGO S19 – I\u0307FADE VIII (8) D\u00fc\u015f\u00fck dereceli yumurtal\u0131k karsinomu (grup A) veya s\u0131n\u0131rda yumurtal\u0131k t\u00fcm\u00f6r\u00fc (grup B – kapal\u0131) olan hastalar i\u00e7in. Ser\u00f6z over karsinomu iyi diferansiye (d\u00fc\u015f\u00fck dereceli...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

IFADE VI (6)<\/a><\/h3><\/header>
\n

NOGGO S13 \/ ENGOT-ov40 – EXPRESSION VI (6)CAROLIN HANNA \u0130LE TANI\u015eIYOR En az 5 y\u0131l \u00f6nce te\u015fhis edilmi\u015f yumurtal\u0131k, fallop t\u00fcp\u00fc ve periton kanseri olan hastalar i\u00e7in YEN\u0130: Daha \u00f6nce...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article>

\n
\n

IFADE XX (20)<\/a><\/h3><\/header>
\n

NOGGO S33\/ \u0130fade XX (20) JI\u0307NEKOLOJI\u0307K T\u00dcM\u00d6R\u00dc OLAN HASTALARA K\u00d6T\u00dc HABER VERI\u0307LMESI\u0307NE I\u0307LI\u0307\u015eKI\u0307N ANKET K\u00f6t\u00fc haber vermek, \u00f6zellikle jinekolojik onkolojide g\u00fcnl\u00fck t\u0131bbi uygulamalar\u0131n \u00f6nemli bir par\u00e7as\u0131d\u0131r. Bu konu\u015fmalar\u0131n s\u0131kl\u0131\u011f\u0131na ra\u011fmen,...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n<\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tAlmanya haritas\u0131na<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

\u00c7al\u0131\u015fmaya genel bak\u0131\u015fYumurtal\u0131k kanseri Burada yumurtal\u0131k kanseri alan\u0131ndaki t\u00fcm g\u00fcncel \u00e7al\u0131\u015fmalar\u0131n bir listesini bulacaks\u0131n\u0131z: \u0130lk tedavi NOGGO ov54 – SCOUT-1 NOGGO ov54 – Scout 1 Beobachtungstudie zur Erfassung von Daten aus der Alltagsroutine von Patient:innen mit Ovarialkarzinom in der Ersttherapie\u00a0 SCOUT-1 ist eine nicht-interventionelle Studie, eine sogenannte Beobachtungstudie mit dem… Daha fazla bilgi edinin N-PLUS […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1893","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/1893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=1893"}],"version-history":[{"count":4,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/1893\/revisions"}],"predecessor-version":[{"id":2013,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/1893\/revisions\/2013"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=1893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}